Cliff Asness's KALV Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 37,572 shares of KalVista Pharmaceuticals, Inc. (KALV) worth $756,325, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in KALV, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 55,975 shares. Largest reduction occurred in Q1 2023, reducing 72,436 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's KalVista Pharmaceuticals (KALV) Holding Value Over Time
Track share changes against reported price movement
Quarterly KalVista Pharmaceuticals (KALV) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +12,906 | Add 52.32% | 37,572 | $20.13 |
| Q4 2025 | -19,940 | Reduce 44.70% | 24,666 | $16.15 |
| Q3 2025 | -2,807 | Reduce 5.92% | 44,606 | $12.18 |
| Q2 2025 | -8,562 | Reduce 15.30% | 47,413 | $11.31 |
| Q1 2025 | +55,975 | New Buy | 55,975 | $11.54 |
| Q4 2024 | -12,354 | Sold Out | 0 | $0.00 |
| Q3 2024 | +12,354 | New Buy | 12,354 | $11.58 |
| Q2 2024 | -10,538 | Sold Out | 0 | $0.00 |
| Q1 2024 | +10,538 | New Buy | 10,538 | $11.86 |
| Q2 2023 | -21,848 | Sold Out | 0 | $0.00 |
| Q1 2023 | -72,436 | Reduce 76.83% | 21,848 | $7.86 |
| Q4 2022 | +94,284 | New Buy | 94,284 | $6.76 |
Cliff Asness's KalVista Pharmaceuticals Investment FAQs
Cliff Asness first purchased KalVista Pharmaceuticals, Inc. (KALV) in Q4 2022, acquiring 94,284 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held KalVista Pharmaceuticals, Inc. (KALV) for 12 quarters since Q4 2022.
Cliff Asness's largest addition to KalVista Pharmaceuticals, Inc. (KALV) was in Q4 2022, adding 94,284 shares worth $637,360.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 37,572 shares of KalVista Pharmaceuticals, Inc. (KALV), valued at approximately $756,325.
As of the Q1 2026 filing, KalVista Pharmaceuticals, Inc. (KALV) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in KalVista Pharmaceuticals, Inc. (KALV) was 94,284 shares, as reported at the end of Q4 2022.